AU2016200713B2 - Peptides capable of reactivating p53 mutants - Google Patents

Peptides capable of reactivating p53 mutants Download PDF

Info

Publication number
AU2016200713B2
AU2016200713B2 AU2016200713A AU2016200713A AU2016200713B2 AU 2016200713 B2 AU2016200713 B2 AU 2016200713B2 AU 2016200713 A AU2016200713 A AU 2016200713A AU 2016200713 A AU2016200713 A AU 2016200713A AU 2016200713 B2 AU2016200713 B2 AU 2016200713B2
Authority
AU
Australia
Prior art keywords
peptide
protein
mutant
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016200713A
Other languages
English (en)
Other versions
AU2016200713A1 (en
Inventor
Moshe Oren
Varda Rotter
Perry Tal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to AU2016200713A priority Critical patent/AU2016200713B2/en
Publication of AU2016200713A1 publication Critical patent/AU2016200713A1/en
Application granted granted Critical
Publication of AU2016200713B2 publication Critical patent/AU2016200713B2/en
Priority to AU2017202806A priority patent/AU2017202806B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016200713A 2013-08-07 2016-02-04 Peptides capable of reactivating p53 mutants Ceased AU2016200713B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016200713A AU2016200713B2 (en) 2013-08-07 2016-02-04 Peptides capable of reactivating p53 mutants
AU2017202806A AU2017202806B2 (en) 2013-08-07 2017-04-28 Peptides capable of reactivating p53 mutants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361862977P 2013-08-07 2013-08-07
US61/862,977 2013-08-07
PCT/IB2014/063777 WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants
AU2016200713A AU2016200713B2 (en) 2013-08-07 2016-02-04 Peptides capable of reactivating p53 mutants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/063777 Division WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202806A Division AU2017202806B2 (en) 2013-08-07 2017-04-28 Peptides capable of reactivating p53 mutants

Publications (2)

Publication Number Publication Date
AU2016200713A1 AU2016200713A1 (en) 2016-05-19
AU2016200713B2 true AU2016200713B2 (en) 2017-02-02

Family

ID=52460737

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016200713A Ceased AU2016200713B2 (en) 2013-08-07 2016-02-04 Peptides capable of reactivating p53 mutants
AU2017202806A Ceased AU2017202806B2 (en) 2013-08-07 2017-04-28 Peptides capable of reactivating p53 mutants

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017202806A Ceased AU2017202806B2 (en) 2013-08-07 2017-04-28 Peptides capable of reactivating p53 mutants

Country Status (12)

Country Link
US (4) US9856289B2 (enExample)
EP (1) EP3030571B1 (enExample)
JP (2) JP6554099B2 (enExample)
CN (1) CN105579464B (enExample)
AU (2) AU2016200713B2 (enExample)
BR (1) BR112016002721A2 (enExample)
CA (1) CA2920147C (enExample)
ES (1) ES2795982T3 (enExample)
HU (1) HUE049292T2 (enExample)
IL (2) IL243944B (enExample)
RU (2) RU2693487C2 (enExample)
WO (1) WO2015019318A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2693487C2 (ru) 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
CN105112377B (zh) * 2015-09-25 2018-10-30 福州迈新生物技术开发有限公司 一株分泌抗p53单克隆抗体的杂交瘤细胞株及其应用
RU2762089C2 (ru) * 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
IL273515B2 (en) 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53
MX2020005879A (es) 2017-12-07 2020-10-07 Reven Ip Holdco Llc Composiciones administrables vía intravenosa que comprenden ácidos de grado farmacéutico y reguladores del ph, y el uso de las mismas para tratar enfermedades de disfunción mitocondrial, enfermedades metabólicas y de disfunción del modelado de huesos y tejidos.
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
KR20220029657A (ko) * 2019-06-12 2022-03-08 리벤 아이피 홀드코 엘엘씨 암 환자의 결과를 향상시키기 위한 방법 및 조성물
JP7402026B2 (ja) 2019-11-27 2023-12-20 株式会社小松製作所 作業機械の制御システム、作業機械、作業機械の制御方法
EP4121441A1 (en) 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
CN111574591B (zh) * 2020-04-29 2021-09-21 西安交通大学医学院第一附属医院 一种多肽及其合成方法
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
EP4263854A4 (en) * 2020-12-21 2025-02-26 Alaunus Biosciences, Inc. PEPTIDASE CLEAVABLE SUBSTRATES AND METHODS OF IDENTIFICATION AND RELATED IDENTIFICATION
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法
CN115466786A (zh) * 2021-06-11 2022-12-13 上海交通大学医学院附属瑞金医院 一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法
WO2026008977A1 (en) * 2024-07-01 2026-01-08 Cambridge Enterprise Limited Protein aggregates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072600A2 (en) * 2002-01-23 2003-09-04 Gardner, Rebecca, Katherine Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) * 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU7238098A (en) * 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US20030224379A1 (en) * 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
WO2002068601A2 (en) * 2001-02-28 2002-09-06 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
JP2009501237A (ja) * 2005-03-14 2009-01-15 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生物活性ｆｕｓ１ペプチドおよびナノ粒子−ポリペプチド複合体
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
SG10201601840RA (en) * 2011-09-09 2016-04-28 Agency Science Tech & Res P53 activating peptides
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AU2013316679B2 (en) * 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
RU2693487C2 (ru) 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
RU2762089C2 (ru) 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072600A2 (en) * 2002-01-23 2003-09-04 Gardner, Rebecca, Katherine Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISSAEVA, NATALIA ET AL., "Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2003), vol. 100.23, pages 13303 - 13307. *

Also Published As

Publication number Publication date
EP3030571B1 (en) 2020-03-18
HK1219742A1 (en) 2017-04-13
HUE049292T2 (hu) 2020-09-28
RU2016106583A3 (enExample) 2018-03-29
JP2016527891A (ja) 2016-09-15
RU2016106583A (ru) 2017-08-30
EP3030571A4 (en) 2017-05-10
RU2019119609A3 (enExample) 2019-12-30
US20180057533A1 (en) 2018-03-01
CN105579464A (zh) 2016-05-11
IL243944B (en) 2019-08-29
RU2721423C2 (ru) 2020-05-19
EP3030571A1 (en) 2016-06-15
US10336789B2 (en) 2019-07-02
RU2693487C2 (ru) 2019-07-03
RU2019119609A (ru) 2019-08-07
CN105579464B (zh) 2021-01-26
US11028127B2 (en) 2021-06-08
US20190315804A1 (en) 2019-10-17
IL243944A0 (en) 2016-04-21
CA2920147C (en) 2022-09-20
US10550152B2 (en) 2020-02-04
US20160215019A1 (en) 2016-07-28
JP6554099B2 (ja) 2019-07-31
BR112016002721A2 (pt) 2018-07-10
US20200095282A1 (en) 2020-03-26
AU2017202806A1 (en) 2017-05-18
CA2920147A1 (en) 2015-02-12
IL268355A (en) 2019-09-26
US9856289B2 (en) 2018-01-02
JP2019214573A (ja) 2019-12-19
AU2017202806B2 (en) 2018-04-05
AU2016200713A1 (en) 2016-05-19
WO2015019318A1 (en) 2015-02-12
ES2795982T3 (es) 2020-11-25

Similar Documents

Publication Publication Date Title
US11028127B2 (en) Peptides capable of reactivating p53 mutants
AU2017214733B2 (en) Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2012090150A2 (en) New cell-penetrating peptides and uses thereof
CA2919855A1 (en) Peptides capable of reactivating p53 mutants
CN115397513A (zh) 改进的抗衰老化合物及其用途
US20220251159A1 (en) Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
HK1219742B (en) Peptides capable of reactivating p53 mutants
WO2019169131A1 (en) Peptide compositions and method of treating human cytomegalovirus infection
HK40101648A (en) Improved anti-senescence compounds and uses for the treatment of cancer
US20230127559A1 (en) Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
WO2025012176A1 (en) Designed ankyrin repeat protein agents targeting brachyury and their use in treatment of chordoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired